Skip to main content

EQRx to Participate in the Jefferies 2022 London Healthcare Conference

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST.

A live and archived webcast of the fireside chat will be available by visiting the News & Events section of EQRx’s website, and selecting Events & Presentations, at investors.eqrx.com.

About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and health systems. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRx_US LinkedIn, Instagram: @eqrxinc.

EQRx™ and Remaking Medicine™ are trademarks of EQRx.

EQRx Contacts:

Media:
Dan Budwick
1AB
dan@1abmedia.com

Investors:
investors@eqrx.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  236.94
-1.68 (-0.70%)
AAPL  277.20
+7.72 (2.86%)
AMD  204.21
-37.90 (-15.65%)
BAC  55.78
+1.33 (2.45%)
GOOG  334.67
-6.03 (-1.77%)
META  675.89
-15.81 (-2.29%)
MSFT  416.26
+5.05 (1.23%)
NVDA  175.46
-4.88 (-2.71%)
ORCL  148.11
-6.56 (-4.24%)
TSLA  408.64
-13.32 (-3.16%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.